Novel ‘learning while doing’ clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies during a pandemic, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials. The trial announced today at UPMC, called UPMC-REMAP-COVID19 learns from similar trials enrolling around the world and uses artificial intelligence to quickly arrive at answers.
- Reliable quality-control of graphene and other 2D materials is routinely possible
- Forecasting elections with a model of infectious diseases
- Researchers uncover health disparities in childhood obesity and access to treatments
- Artificial intelligence (AI)-aided disease prediction
- Physicists circumvent centuries-old theory to cancel magnetic fields